9月24日，九州通涨0.00%，成交额1.23亿元。两融数据显示，当日九州通获融资买入额1301.45万元， 融资偿还1412.00万元，融资净买入-110.55万元。截至9月24日，九州通融资融券余额合计7.60亿元。 分红方面，九州通A股上市后累计派现52.67亿元。近三年，累计派现29.11亿元。 机构持仓方面，截止2025年6月30日，九州通十大流通股东中，香港中央结算有限公司位居第七大流通 股东，持股9024.99万股，相比上期增加873.97万股。 责任编辑：小浪快报 融券方面，九州通9月24日融券偿还1.24万股，融券卖出10.77万股，按当日收盘价计算，卖出金额53.20 万元；融券余量111.89万股，融券余额552.75万元，超过近一年90%分位水平，处于高位。 资料显示，九州通医药集团股份有限公司位于湖北省武汉市汉阳区龙兴西街5号，成立日期1999年3月9 日，上市日期2010年11月2日，公司主营业务涉及数字化医药分销与供应链业务、总代品牌推广业务、 医药工业自产及OEM业务、医药零售与加盟业务、数字物流与供应链解决方案、医疗健康与技术增值 服务等六大方面。主营业务收入构成为：分销分部 ...

Core Viewpoint - The pharmaceutical distribution industry in China is experiencing a significant divergence in performance between regional and national companies, influenced by ongoing healthcare reforms and market dynamics. Group 1: Performance of Regional Companies - Liuyao Group, a leading regional pharmaceutical distributor, reported a decline in both revenue and net profit for the first half of 2025, with revenue at 10.30 billion yuan, down 3.21% year-on-year, and net profit at 429 million yuan, down 7.52% [3] - The decline in Liuyao Group's performance is attributed to stricter control over drug expenditures by medical institutions and the impact of centralized procurement policies, leading to reduced sales and profit margins [3][4] - Other regional companies, such as Renmin Tongtai, also faced challenges, with total revenue of 5.15 billion yuan and a significant drop in wholesale business revenue due to intensified competition and procurement reforms [3] Group 2: Performance of National Companies - National distributor Jiuzhoutong reported a revenue increase of 5.10% year-on-year, reaching 67.63 billion yuan, and a net profit increase of 19.70% [2] - Jiuzhoutong's growth is driven by robust performance in its digital pharmaceutical distribution and supply chain business, which generated 67.63 billion yuan, up 6.04% [2] - The company also benefited from the issuance of public REITs, which added 438 million yuan to its net profit, showcasing a successful strategy to enhance cash flow and reduce reliance on traditional debt financing [8] Group 3: Strategic Shifts and Future Outlook - Liuyao Group is transitioning from a traditional distributor to a health service solution provider, aiming to create a comprehensive health ecosystem that includes production, distribution, sales, and health management [7] - North University Medicine, heavily reliant on its partnership with Peking University International Hospital, faces significant revenue and profit declines due to the expiration of its service contract, projecting a revenue drop of approximately 600 million yuan in the second half of 2025 [4] - The industry is witnessing a trend towards diversification and digital transformation, with companies exploring new marketing and service models to adapt to the competitive landscape [6][5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 81.11 billion yuan in H1 2025, representing a year-on-year increase of 5.10%. The net profit attributable to the parent company was 1.446 billion yuan, up by 19.70% [4] - The company is expected to benefit from its "Three New and Two Transformations" strategic layout, which is anticipated to drive growth potential [4] - The company has adjusted its profit forecasts for 2025-2026 and added a new forecast for 2027, expecting net profits of 2.633 billion yuan, 2.854 billion yuan, and 3.118 billion yuan for 2025, 2026, and 2027 respectively [4] Financial Performance Summary - In H1 2025, the company's gross margin was 7.56%, a decrease of 0.35 percentage points, while the net margin increased by 0.25 percentage points to 1.87% [4] - The company's digital pharmaceutical distribution and supply chain business generated revenue of 67.634 billion yuan, up by 6.04% [5] - The company has seen a steady growth in its logistics supply chain solutions, which are expected to enhance operational performance [6] Financial Forecasts - The company’s projected revenues for 2025, 2026, and 2027 are 161.17 billion yuan, 172.66 billion yuan, and 185.53 billion yuan respectively, with year-on-year growth rates of 6.2%, 7.1%, and 7.5% [8] - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.52 yuan, 0.57 yuan, and 0.62 yuan respectively [8] - The price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are expected to be 10.1, 9.3, and 8.5 respectively [8]

Group 1 - The core viewpoint of the news is that Jiuzhoutong has shown stable financial performance with a slight increase in revenue and net profit, while also experiencing changes in stockholder dynamics and financing activities [2][3]. Group 2 - As of June 30, Jiuzhoutong reported a revenue of 81.11 billion, representing a year-on-year growth of 5.10%, and a net profit attributable to shareholders of 1.446 billion, which is a 19.70% increase compared to the previous year [2]. - The company has a total of 41,700 shareholders, a decrease of 12.92% from the previous period, while the average circulating shares per person increased by 14.84% to 120,824 shares [2]. - Jiuzhoutong has cumulatively distributed dividends of 5.267 billion since its A-share listing, with 2.911 billion distributed in the last three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited is the seventh largest circulating shareholder, holding 90.2499 million shares, an increase of 8.7397 million shares from the previous period [3]. Group 3 - On August 26, Jiuzhoutong's stock price remained unchanged at 0.00%, with a trading volume of 319 million [1]. - The financing buy-in amount on that day was 38.9818 million, while the financing repayment was 19.9517 million, resulting in a net financing buy-in of 19.03 million [1]. - The total balance of margin trading and securities lending for Jiuzhoutong reached 642 million, with the financing balance accounting for 2.32% of the circulating market value, which is below the 20th percentile level over the past year [1]. - In terms of securities lending, Jiuzhoutong repaid 3,300 shares and sold 191,700 shares, with a selling amount of 1.0428 million, while the remaining securities lending volume was 912,600 shares, exceeding the 90th percentile level over the past year [1].